Could not agree more. Show us the [partnership] money SI.
The FDA is not without fault in MSB's prospects, or indeed the continued terrible prognosis of steroid refractory GvHD sufferers who will basically be dead within 2 years of painful suffering.
But nor is MSB in some poor trial decisions, strategic decisions and failure to encourage a decent partnership in a stem cell back drop that sees regulatory developments in hematopoietic stem cells in blood cancers week after week. There is a crying shortcoming in donors for approved practices:
"According to data from the Be the Match Registry, 79% of White patients are able to find a match in the stem cell donor registry compared with 29% of Black patients, 47% of Asian/Pacific Islander patients, and 48% of Hispanic/Latino patients." (October, 2023)
MSB indisputably a world leader in trialing but its getting a bit old:
https://www.bloomberg.com/press-releases/2017-12-07/mesoblast-named-global-technology-leader-in-cell-therapy-industry
....and beaten to the punch SI. Pull your finger out:
https://www.europeanpharmaceuticalreview.com/news/181618/fda-approves-allogeneic-stem-cell-transplant-therapy/
Stop illuding to it and just get a partnership announced already.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |